“…In our experiments, the remote effects of early treatments were analyzed [78] as the result of biologically active substance injections which are different during the period from the 2nd to 6th postnatal day (mainly). Newborn mice and rat pups of several genotypes were injected with ACTH 4-10 , Semax (the peptide resistant to endopeptidase cleavage activity, the synthetic analogue of ACTH 4-10 fragment (see [79]), ketamine (nonconcurrent NMDA-receptor antagonist), caffeine (A1 type adenosine receptor antagonist), pyracetame, melatonin, buspirone (5НТ-2А-receptors agonist), L-NAME (NOS inhibitor), and levetiracetam (anticonvulsant).…”